These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22505536)

  • 1. Circulating levels of HER-2/neu oncoprotein in breast cancer.
    Molina R; Escudero JM; Muñoz M; Augé JM; Filella X
    Clin Chem Lab Med; 2012 Jan; 50(1):5-21. PubMed ID: 22505536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
    Molina R; Augé JM; Escudero JM; Filella X; Zanon G; Pahisa J; Farrus B; Muñoz M; Velasco M
    Tumour Biol; 2010 Jun; 31(3):171-80. PubMed ID: 20361287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
    Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
    Clin Chem; 2003 Oct; 49(10):1579-98. PubMed ID: 14500583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum her-2/neu level and related factors in patients with breast cancer].
    Yuan P; Xu BH; Zhang C; Qi J
    Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum HER-2/neu in the management of breast cancer patients.
    Lüftner D; Lüke C; Possinger K
    Clin Biochem; 2003 Jun; 36(4):233-40. PubMed ID: 12810150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
    Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
    Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS; Fletcher JA
    Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
    Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
    Clin Breast Cancer; 2004 Jun; 5(2):105-16. PubMed ID: 15245613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.
    Papila C; Uzun H; Balci H; Zerdali H; Sezgin C; Can G; Yanardag H
    Med Oncol; 2009; 26(2):151-6. PubMed ID: 18855148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
    Yamauchi H; O'Neill A; Gelman R; Carney W; Tenney DY; Hösch S; Hayes DF
    J Clin Oncol; 1997 Jul; 15(7):2518-25. PubMed ID: 9215820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.
    Thriveni K; Deshmane V; Bapsy PP; Krishnamoorthy L; Ramaswamy G
    Indian J Med Res; 2007 Feb; 125(2):137-42. PubMed ID: 17431282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue expression and serum levels of HER-2/neu in patients with breast cancer.
    Krainer M; Brodowicz T; Zeillinger R; Wiltschke C; Scholten C; Seifert M; Kubista E; Zielinski CC
    Oncology; 1997; 54(6):475-81. PubMed ID: 9394844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
    Lüftner D; Cheli C; Mickelson K; Sampson E; Possinger K
    Int J Biol Markers; 2004; 19(3):175-82. PubMed ID: 15503818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer.
    Cook GB; Neaman IE; Goldblatt JL; Cambetas DR; Hussain M; Lüftner D; Yeung KK; Chan DW; Schwartz MK; Allard WJ
    Anticancer Res; 2001; 21(2B):1465-70. PubMed ID: 11396233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
    Schulze G
    Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
    Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
    Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.